J. Tol

1.6k total citations
22 papers, 1.2k citations indexed

About

J. Tol is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, J. Tol has authored 22 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 4 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in J. Tol's work include Colorectal Cancer Treatments and Studies (9 papers), Cancer Treatment and Pharmacology (6 papers) and Gastric Cancer Management and Outcomes (5 papers). J. Tol is often cited by papers focused on Colorectal Cancer Treatments and Studies (9 papers), Cancer Treatment and Pharmacology (6 papers) and Gastric Cancer Management and Outcomes (5 papers). J. Tol collaborates with scholars based in Netherlands, United States and Belgium. J. Tol's co-authors include Cornelis J.A. Punt, Miriam Koopman, Allert H. Vos, Annemieke Cats, Irıs D. Nagtegaal, Linda Mol, Ninja Antonini, Jolanda Schrama, C. J. Rodenburg and Nikki Knijn and has published in prestigious journals such as Journal of Clinical Oncology, Neurology and British Journal of Cancer.

In The Last Decade

J. Tol

22 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J. Tol Netherlands	11	878	339	265	258	234	22	1.2k
Diana L. Hanna United States	17	600 0.7×	250 0.7×	122 0.5×	258 1.0×	182 0.8×	75	1.0k
Eun Yoon Cho South Korea	19	549 0.6×	384 1.1×	162 0.6×	357 1.4×	193 0.8×	50	1.6k
Peirong Ding China	19	840 1.0×	240 0.7×	177 0.7×	233 0.9×	301 1.3×	109	1.3k
Ru Jia China	19	833 0.9×	318 0.9×	73 0.3×	217 0.8×	155 0.7×	50	1.6k
Mauro Loi Italy	23	586 0.7×	716 2.1×	321 1.2×	249 1.0×	70 0.3×	124	1.5k
Edoardo Francini Italy	20	554 0.6×	632 1.9×	215 0.8×	291 1.1×	83 0.4×	73	1.2k
Peng Du China	18	590 0.7×	352 1.0×	226 0.9×	276 1.1×	76 0.3×	51	1.6k
Louise C. Connell United States	8	1.2k 1.4×	347 1.0×	64 0.2×	107 0.4×	191 0.8×	31	1.6k
Jen‐Kou Lin Taiwan	21	672 0.8×	262 0.8×	92 0.3×	142 0.6×	275 1.2×	56	1.1k
Shisuo Du China	18	471 0.5×	241 0.7×	157 0.6×	212 0.8×	54 0.2×	77	1.2k

Countries citing papers authored by J. Tol

Since Specialization

Citations

This map shows the geographic impact of J. Tol's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Tol with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Tol more than expected).

Fields of papers citing papers by J. Tol

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Tol. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Tol. The network helps show where J. Tol may publish in the future.

Co-authorship network of co-authors of J. Tol

This figure shows the co-authorship network connecting the top 25 collaborators of J. Tol. A scholar is included among the top collaborators of J. Tol based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Tol. J. Tol is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Konings, Inge R., Vincent van der Noort, E. van den Pol, et al.. (2025). 487MO Overall survival with first versus second-line use of CDK4/6 inhibitors in HR+/HER2- advanced breast cancer. Annals of Oncology. 36. S379–S380. 1 indexed citations

Kent, Stephen B. H., Inge R. Konings, Vincent van der Noort, et al.. (2024). 352P Cost-effectiveness of CDK4/6 inhibitors in first- vs second-line for advanced breast cancer (ABC) in the phase III SONIA trial (BOOG 2017-03). Annals of Oncology. 35. S364–S364. 1 indexed citations

Tol, J., et al.. (2024). Differences in the Incidence of Hypotension and Hypertension between Sexes during Non-Cardiac Surgery: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine. 13(3). 666–666. 1 indexed citations

Geurts, Sandra M. E., J. Tol, Birgit E. P. J. Vriens, et al.. (2024). 202P Complete response rates, treatment patterns and survival outcomes in patients treated with first-line pertuzumab-based therapy in HER2-positive advanced breast cancer: A SONABRE study. ESMO Open. 9. 103224–103224. 1 indexed citations

Schuurmans, Jaap, J. Tol, Niels van Mourik, et al.. (2024). Hypotension during intensive care stay and mortality and morbidity: a systematic review and meta-analysis. Intensive Care Medicine. 50(4). 516–525. 9 indexed citations

Tol, J., Lotte E. Terwindt, Marije Wijnberge, et al.. (2024). Performance of a Machine Learning Algorithm to Predict Hypotension in Spontaneously Breathing Non-Ventilated Post-Anesthesia and ICU Patients. Journal of Personalized Medicine. 14(2). 210–210. 1 indexed citations

Geurts, Sandra M. E., Frans Erdkamp, Joan B. Heijns, et al.. (2023). 233P Treatment pattern and outcomes for the first two lines of chemotherapy in patients diagnosed with metastatic triple-negative breast cancer, results from the Dutch SONABRE Registry. ESMO Open. 8(1). 101421–101421. 1 indexed citations

Gebhart, Géraldine, Laetitia E. Lamberts, Zéna Wimana, et al.. (2015). Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. Annals of Oncology. 27(4). 619–624. 265 indexed citations

Haan, Anton F. J. de, et al.. (2015). Does diastolic dysfunction precede systolic dysfunction in trastuzumab-induced cardiotoxicity? Assessment with multigated radionuclide angiography (MUGA). Journal of Nuclear Cardiology. 23(4). 824–832. 19 indexed citations

10.

Delsing, Corine, Chantal P. Bleeker‐Rovers, Frank L. van de Veerdonk, et al.. (2012). Association of esophageal candidiasis and squamous cell carcinoma. Medical Mycology Case Reports. 1(1). 5–8. 44 indexed citations

11.

Knijn, Nikki, Leonie J. Mekenkamp, M. Elisa Vink-Börger, et al.. (2011). KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. British Journal of Cancer. 104(6). 1020–1026. 235 indexed citations

12.

Knijn, Nikki, J. Tol, Miriam Koopman, et al.. (2010). The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients. European Journal of Cancer. 47(3). 369–374. 39 indexed citations

13.

Tol, J., Miriam Koopman, Michael Craig Miller, et al.. (2009). Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents. Annals of Oncology. 21(5). 1006–1012. 178 indexed citations

14.

Tol, J., Miriam Koopman, C. J. Rodenburg, et al.. (2008). A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. Annals of Oncology. 19(4). 734–738. 167 indexed citations

15.

Tol, J., Annemieke Cats, Linda Mol, et al.. (2008). Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation. Investigational New Drugs. 26(4). 393–397. 53 indexed citations

16.

Tol, J. & Cornelis J. A. Punt. (2007). Targeted therapy in advanced colorectal cancer, an update. Targeted Oncology. 2(3). 165–172. 3 indexed citations

17.

Tol, J., Miriam Koopman, C. J. Rodenburg, et al.. (2007). 3000 ORAL Randomised phase III study of capecitabine, oxaliplatin and bevacizumab (CAPOX-B) with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim safety analysis. European Journal of Cancer Supplements. 5(4). 234–235. 4 indexed citations

18.

Tol, J. & C.J.A. Punt. (2006). Treatment of liver metastases from colorectal cancer.. PubMed. 64(5). 133–5. 9 indexed citations

19.

Dermaut, Bart, Marc Cruts, Jeanine J. Houwing‐Duistermaat, et al.. (2000). The α2-macroglobulin gene in AD. Neurology. 55(5). 678–684. 53 indexed citations

20.

Tol, J., Gerwin Roks, Arjen J. C. Slooter, & Cornelia M. van Duijn. (1999). Genetic and environmental factors in Alzheimer's disease.. PubMed. 155 Suppl 4. S10–6. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact